JPRN-UMIN000008771已完成2 期
Phase II study of pemetrexed or pemetrexed plus bevacizumab for previously untreated elderly non-squamous non-small cell lung cancer - Phase II trial of PEM or PEM/BEV
ung Oncology Group in Kyushu, Japan (LOGIK)0 个研究点目标入组 82 人开始时间: 2012年8月27日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 82
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 75years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) symptomatic brain metastasis 2) complications as follows: hemoptysis, arterial and venous thromboembolism, uncontrolled hypertension, perforation of the digestive tract/severe fistula/bronchoesophageal fistula, inflammation in abdominal cavity, congenital bleeding predisponency/abnormality of hemostasis, uncontrolled diabetes 3) operation within 28 days 4) planning of thoracic radiotherapy in bevacizumab therapy 5) symptomatic pericardial effusion 6) symptomatic SVC syndrome 7) interstitial pneumonia confirmed in chest X-ray 8) psychotic disease judged should not to participate the trial 9) other inadequacy cases judged by attending physician
研究者
相似试验
进行中（未招募）
不适用
A phase 2 study of Pemetrexed versus Pemetrexed + Erlotinib in second line Treatment for NSCLCPatients who have histologically or cytologically documented diagnosis of Non Small Cell Lung Cancer (Stage IIIA, IIIB or IV at entry), with progressive disease after treatment with 1 prior chemotherapy regimen, who are considered for second line therapy.MedDRA version: 8.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSEUCTR2006-005118-11-ATEli lilly and Company Limited150
进行中（未招募）
不适用
A phase 2 study of Pemetrexed versus Pemetrexed + Erlotinib in second line Treatment for NSCLCEUCTR2006-005118-11-HUEli lilly and Company Limited150
进行中（未招募）
不适用
A Phase 2 Study of Pemetrexed versus Pemetrexed + Erlotinib in Second-Line Treatment in Patients with Nonsquamous NSCLCEUCTR2006-005118-11-SEEli lilly and Company Limited200
进行中（未招募）
不适用
A Phase 2 Study of Pemetrexed versus Pemetrexed + Erlotinib in Second-Line Treatment in Patients with Nonsquamous NSCLCPatients who have histologically or cytologically documented diagnosis of nonsquamous NSCLC (Stage IIIA, IIIB or IV at entry), with progressive disease after treatment with 1 prior chemotherapy regimen for locally advanced or metastatic disease, who are considered for second line therapy and who meet the other disease criteria.MedDRA version: 8.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSEUCTR2006-005118-11-DEEli lilly and Company Limited200
招募中
2 期
Phase II study of pemetrexed for advanced or relapsed non-squamous non-small-cell lung cancer in elderly patientson-squamous non-small cell lung cancer in elderly chemo-naive patientsJPRN-UMIN000004018Juntendo University30